Akoya Biosciences, Inc.
AKYA · NASDAQ
3/31/2025 | 12/31/2024 | 9/30/2024 | 6/30/2024 | |
|---|---|---|---|---|
| Revenue | $16,639 | $21,344 | $18,814 | $23,164 |
| % Growth | -22% | 13.4% | -18.8% | – |
| Cost of Goods Sold | $6,768 | $6,955 | $7,090 | $9,778 |
| Gross Profit | $9,871 | $14,389 | $11,724 | $13,386 |
| % Margin | 59.3% | 67.4% | 62.3% | 57.8% |
| R&D Expenses | $5,557 | $4,429 | $4,474 | $5,288 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $17,580 | $15,688 | $14,672 | $19,094 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $146 | $0 | $927 | $0 |
| Operating Expenses | $23,283 | $20,117 | $20,073 | $24,382 |
| Operating Income | -$13,412 | -$5,712 | -$8,349 | -$11,084 |
| % Margin | -80.6% | -26.8% | -44.4% | -47.9% |
| Other Income/Exp. Net | -$2,192 | -$2,495 | -$2,140 | -$2,018 |
| Pre-Tax Income | -$15,604 | -$8,207 | -$10,489 | -$13,102 |
| Tax Expense | $48 | -$8 | $44 | $47 |
| Net Income | -$15,652 | -$8,199 | -$10,533 | -$13,149 |
| % Margin | -94.1% | -38.4% | -56% | -56.8% |
| EPS | -0.32 | -0.17 | -0.21 | -0.27 |
| % Growth | -88.2% | 19% | 22.2% | – |
| EPS Diluted | -0.32 | -0.17 | -0.21 | -0.27 |
| Weighted Avg Shares Out | 49,665 | 49,560 | 49,503 | 49,420 |
| Weighted Avg Shares Out Dil | 49,665 | 49,560 | 49,503 | 49,420 |
| Supplemental Information | – | – | – | – |
| Interest Income | $313 | $380 | $521 | $668 |
| Interest Expense | $2,492 | $2,586 | $2,625 | $2,606 |
| Depreciation & Amortization | $1,798 | $1,852 | $1,825 | $1,926 |
| EBITDA | -$11,314 | -$3,769 | -$6,039 | -$8,570 |
| % Margin | -68% | -17.7% | -32.1% | -37% |